Brain Natriuretic Peptide Concentration in Dogs with Heart Disease and Congestive Heart Failure

Journal of Veterinary Internal Medicine

Volumn 17, Issue 2, 2003, Pages 172-177

  MacDonald, Kristin A ^a,b   Kittleson, Mark D ^a   Munro, Coralie ^a   Kass, Philip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diagnostic test; Mortality; Myxomatous mitral valve disease

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCODONE; SPIRONOLACTONE; BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DOG; ECHOCARDIOGRAPHY; HEART DISEASE; MITRAL VALVE DISEASE; MITRAL VALVE REGURGITATION; NONHUMAN; THORAX RADIOGRAPHY; ANIMAL; BLOOD; DOG DISEASE; MORTALITY; PREDICTION AND FORECASTING;

CANIS FAMILIARIS;

ANIMALS; DOG DISEASES; DOGS; HEART FAILURE, CONGESTIVE; MITRAL VALVE INSUFFICIENCY; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS;

EID: 0038317942     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2003)017<0172:BNPCID>2.3.CO;2     Document Type: Article

References (61)

1. Brookes CI, Kemp MW, Hooper J, et al. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis 1997;6:608-612.
2. Hasegawa K, Fujiwara H, Doyama K, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-380.
3. Mizuno Y, Yoshimura M, Harada E, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 2000;86:1036-1040, A11.
4. Fleischer D, Espiner EA, Yandle TG, et al. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea. N Z Med J 1997;110:71-74.
5. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-385.
6. Klinge R, Hystad M, Kjekshus J, et al. An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure. Scand J Clin Lab Invest 1998;58:683-691.
7. De Boer RA, Henning RH, Suurmeijer AJ, et al. Early expression of natriuretic peptides and SERCA in mild heart failure: Association with severity of the disease. Int J Cardiol 2001;78:5-12.
8. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
9. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-516 (see comments).
10. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-1969.
11. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684-H1689.
12. Haggstrom J, Hansson K, Kvart C, et al. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease. J Vet Cardiol 2000;2:7-16.
13. Asano K, Masuda K, Okumura M, et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. J Vet Med Sci 1999;61:523-529.
14. Magga J, Vuolteenaho O, Tokola H, et al. B-type natriuretic peptide: A myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann Med 1998;30(Suppl 1):39-45.
15. Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length. Circulation 2000;102:3074-3079.
16. Ikeda T, Matsuda K, Itoh H, et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 1997;133:307-314.
17. Lang CC, Choy AM, Struthers AD. Atrial and brain natriuretic peptides: A dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci (Lond) 1992;83:519-527.
18. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Lond) 1998;95:519-529.
19. Magga J, Marttila M, Mantymaa P, et al. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology 1994;134:2505-2515.
20. Lang CC, Prasad N, McAlpine HM, et al. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. Am Heart J 1994;127:1635-1636.
21. Moe GW, Grima EA, Wong NL, et al. Dual natriuretic peptide system in experimental heart failure. J Am Coll Cardiol 1993;22:891-898.
22. Brookes CI, Kemp MW, Hooper J, et al. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis 1997;6:608-612.
23. Cheung BM. Plasma concentration of brain natriuretic peptide is related to diastolic function in hypertension. Clin Exp Pharmacol Physiol 1997;24:966-968.
24. Waku S, Iida N, Ishihara T. Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function. Methods Inf Med 2000;39:249-253.
25. Nishigaki K, Tomita M, Kagawa K, et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996;28:1234-1242.
26. Briguori C, Betocchi S, Manganelli F, et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J 2001;22:1328-1336.
27. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
28. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-374.
29. Kittleson MD, Kienle R. Small Animal Cardiovascular Medicine. St Louis, MO: Mosby; 1998:104.
30. Cornell CC, Kittleson MD, Della Torre P, et al. Allometric scaling of m-mode variables in normal adult dogs. Proceedings of the 11th European Society of Veterinary Internal Medicine, Dublin, Ireland, September 9, 2001.
31. Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194-199.
32. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001;37:386-391.
33. McDonagh TA, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001;86:21-26.
34. Eriksson AS, Jarvinen AK, Eklund KK, et al. Effect of age and body weight on neurohumoral variables in healthy Cavalier King Charles spaniels. Am J Vet Res 2001;62:1818-1824.
35. Richards AM, Crozier IG, Espiner EA, et al. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension 1993;22:231-236.
36. Wilkins MA, Su XL, Palayew MD, et al. The effects of posture change and continuous positive airway pressure on cardiac natriuretic peptides in congestive heart failure. Chest 1995;107:909-915.
37. Lang CC, Choy AM, Turner K, et al. The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man. J Hypertens 1993;11:737-741.
38. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens 1992;10:907-912.
39. Takeda T, Kohno M. Brain natriuretic peptide in hypertension. Hypertens Res 1995;18:259-266.
40. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 1996;9:432-436.
41. Woods RL, Jones MJ. Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs. Am J Physiol 1999;276:R1443-R1452.
42. Nishida Y, Morita H, Minamino N, et al. Effects of brain natriuretic peptide on hemodynamics and renal function in dogs. Jpn J Physiol 1990;40:531-540.
43. Appel RG. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol 1992;262:F911-F918.
44. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812-818.
45. Arjona AA, Hsu CA, Wrenn DS, Hill NS. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen Pharmacol 1997;28:387-392.
46. Ogawa Y, Tamura N, Chusho H, Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 2001;79:723-729.
47. Tamamori M, Ito H, Hiroe M, et al. Stimulation of collagen synthesis in rat cardiac fibroblasts by exposure to hypoxic culture conditions and suppression of the effect by natriuretic peptides. Cell Biol Int 1997;21:175-180.
48. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995;96:1059-1065.
49. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999;134:437-444.
50. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995;96:1280-1287.
51. Thibault G, Charbonneau C, Bilodeau J, et al. Rat brain natriuretic peptide is localized in atrial granules and released into the circulation. Am J Physiol 1992;263:R301-R309.
52. Ogawa T, Linz W, Stevenson M, et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 1996;93:2059-2067.
53. Bianciotti LG, De Bold AJ. Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension. Cardiovasc Res 2001;49:808-816.
54. Ruskoaho H. Atrial natriuretic peptide: Synthesis, release, and metabolism. Pharmacol Rev 1992;44:479-602.
55. Bianciotti LG, De Bold AJ. Effect of selective ET(A) receptor blockade on natriuretic peptide gene expression in DOCA-salt hypertension. Am J Physiol Heart Circ Physiol 2000;279:H93-H101.
56. Liang F, Kovacic-Milivojevic B, Chen S, et al. Signaling mechanisms underlying strain-dependent brain natriuretic peptide gene transcription. Can J Physiol Pharmacol 2001;79:640-645.
57. Liang F, Wu J, Garami M, Gardner DG. Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes. J Biol Chem 1997;272:28050-28056.
58. Arai M, Yoguchi A, Iso T, et al. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol 1995;268:H2084-H2091.
59. Magga J, Vuolteenaho O, Marttila M, Ruskoaho H. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: Acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro. Circulation 1997;96:3053-3062.
60. Liang F, Gardner DG. Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes. J Biol Chem 1998;273:14612-14619.
61. Tanaka M, Hiroe M, Nishikawa T, et al. Cellular localization and structural characterization of natriuretic peptide-expressing ventricular myocytes from patients with dilated cardiomyopathy. J Histochem Cytochem 1994;42:1207-1214.